Skip to main content
Erschienen in: Osteoporosis International 5/2010

01.05.2010 | Original Article

Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and Garvan nomogram

verfasst von: S. K. Sandhu, N. D. Nguyen, J. R. Center, N. A. Pocock, J. A. Eisman, T. V. Nguyen

Erschienen in: Osteoporosis International | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Summary

We evaluated the prognostic accuracy of fracture risk assessment tool (FRAX™) and Garvan algorithms in an independent Australian cohort. The results suggest comparable performance in women but relatively poor fracture risk discrimination in men by FRAX™. These data emphasize the importance of external validation before widespread clinical implementation of prognostic tools in different cohorts.

Introduction

Absolute risk assessment is now recognized as a preferred approach to guide treatment decision. The present study sought to evaluate accuracy of the FRAX™ and Garvan algorithms for predicting absolute risk of osteoporotic fracture (hip, spine, humerus, or wrist), defined as major in FRAX™, in a clinical setting in Australia.

Methods

A retrospective validation study was conducted in 144 women (69 fractures and 75 controls) and 56 men (31 fractures and 25 controls) aged between 60 and 90 years. Relevant clinical data prior to fracture event were ascertained. Based on these variables, predicted 10-year probabilities of major fracture were calculated from the Garvan and FRAX™ algorithms, using US (FRAX-US) and UK databases (FRAX-UK). Area under the receiver operating characteristic curves (AUC) was computed for each model.

Results

In women, the average 10-year probability of major fracture was consistently higher in the fracture than in the nonfracture group: Garvan (0.33 vs. 0.15), FRAX-US (0.30 vs. 0.19), and FRAX-UK (0.17 vs. 0.10). In men, although the Garvan model yielded higher average probability of major fracture in the fracture group (0.32 vs. 0.14), the FRAX™ algorithm did not: FRAX-US (0.17 vs. 0.19) and FRAX-UK (0.09 vs. 0.12). In women, AUC for the Garvan, FRAX-US, and FRAX-UK algorithms were 0.84, 0.77, and 0.78, respectively, vs. 0.76, 0.54, and 0.57, respectively, in men.

Conclusion

In this analysis, although both approaches were reasonably accurate in women, FRAX™ discriminated fracture risk poorly in men. These data support the concept that all algorithms need external validation before clinical implementation.
Literatur
1.
Zurück zum Zitat Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788CrossRefPubMed Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788CrossRefPubMed
2.
Zurück zum Zitat Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T (1993) The lifetime risk of developing breast cancer. J Natl Cancer Inst 85:892–897CrossRefPubMed Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T (1993) The lifetime risk of developing breast cancer. J Natl Cancer Inst 85:892–897CrossRefPubMed
3.
Zurück zum Zitat Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882CrossRefPubMed Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882CrossRefPubMed
4.
Zurück zum Zitat Tosteson AN, Gottlieb DJ, Radley DC, Fisher ES, Melton LJ 3rd (2007) Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int 18:1463–1472CrossRefPubMed Tosteson AN, Gottlieb DJ, Radley DC, Fisher ES, Melton LJ 3rd (2007) Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int 18:1463–1472CrossRefPubMed
5.
Zurück zum Zitat Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11:460–466CrossRefPubMed Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11:460–466CrossRefPubMed
6.
Zurück zum Zitat Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 180:S18–S22PubMed Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 180:S18–S22PubMed
7.
Zurück zum Zitat Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969–1975CrossRefPubMed Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969–1975CrossRefPubMed
8.
Zurück zum Zitat Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112CrossRefPubMed Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112CrossRefPubMed
9.
Zurück zum Zitat Nguyen ND, Eisman JA, Center JR, Nguyen TV (2007) Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab 92:955–962CrossRefPubMed Nguyen ND, Eisman JA, Center JR, Nguyen TV (2007) Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab 92:955–962CrossRefPubMed
10.
Zurück zum Zitat Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38:694–700CrossRefPubMed Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38:694–700CrossRefPubMed
11.
Zurück zum Zitat Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773CrossRefPubMed Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773CrossRefPubMed
12.
Zurück zum Zitat Nguyen ND, Pongchaiyakul C, Center JR, Eisman JA, Nguyen TV (2005) Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 20:1921–1928CrossRefPubMed Nguyen ND, Pongchaiyakul C, Center JR, Eisman JA, Nguyen TV (2005) Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 20:1921–1928CrossRefPubMed
13.
Zurück zum Zitat Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed
14.
Zurück zum Zitat Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109–1117CrossRefPubMed Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109–1117CrossRefPubMed
15.
Zurück zum Zitat Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444CrossRefPubMed Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444CrossRefPubMed
16.
Zurück zum Zitat Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMed Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMed
17.
Zurück zum Zitat Obuchowski NA, Zhou XH (2002) Prospective studies of diagnostic test accuracy when disease prevalence is low. Biostatistics 3:477–492CrossRefPubMed Obuchowski NA, Zhou XH (2002) Prospective studies of diagnostic test accuracy when disease prevalence is low. Biostatistics 3:477–492CrossRefPubMed
18.
19.
Zurück zum Zitat Nguyen TV, Center JR, Eisman JA (2005) Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 20:1195–1201CrossRefPubMed Nguyen TV, Center JR, Eisman JA (2005) Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 20:1195–1201CrossRefPubMed
20.
Zurück zum Zitat Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471CrossRefPubMed Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471CrossRefPubMed
21.
Zurück zum Zitat Torgerson DJ, Kanis JA (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. OJM 88:135–139 Torgerson DJ, Kanis JA (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. OJM 88:135–139
22.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–97CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–97CrossRef
23.
Zurück zum Zitat Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G (2005) Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 11:1786–1790CrossRefPubMed Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G (2005) Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 11:1786–1790CrossRefPubMed
24.
Zurück zum Zitat Wong GL, Hui AY, Wong VW, Chan FK, Sung JJ, Chan HL (2005) A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol 100:2205–2211CrossRefPubMed Wong GL, Hui AY, Wong VW, Chan FK, Sung JJ, Chan HL (2005) A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol 100:2205–2211CrossRefPubMed
25.
Zurück zum Zitat Bartley AN, Ross DW (2002) Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch Pathol Lab Med 126:456–458PubMed Bartley AN, Ross DW (2002) Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch Pathol Lab Med 126:456–458PubMed
26.
Zurück zum Zitat Smeenk JM, Stolwijk AM, Kremer JA, Braat DD (2000) External validation of the Templeton model for predicting success after IVF. Hum Reprod 15:1065–1068CrossRefPubMed Smeenk JM, Stolwijk AM, Kremer JA, Braat DD (2000) External validation of the Templeton model for predicting success after IVF. Hum Reprod 15:1065–1068CrossRefPubMed
27.
Zurück zum Zitat Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ (2005) Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 140:183–189CrossRefPubMed Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ (2005) Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 140:183–189CrossRefPubMed
Metadaten
Titel
Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and Garvan nomogram
verfasst von
S. K. Sandhu
N. D. Nguyen
J. R. Center
N. A. Pocock
J. A. Eisman
T. V. Nguyen
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 5/2010
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-1026-7

Weitere Artikel der Ausgabe 5/2010

Osteoporosis International 5/2010 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.